With the incidence of cardiac disease on a constant growth curve, a test modality that can provide specific, inexpensive screening tools for cardiovascular disease (CVD) before the onset of symptoms, is like the proverbial "license to print money," and a large menu of tests have been developed, including serum lipids, hypercoagulation factors, enzyme and protein markers, genetic makeup, and even tests for certain viral infections. This report presents diagnostic modalities for the detection of CVD throughout the continuum of the disease progression including: congestive heart failure, unstable angina, myocardial infarction, stroke and other manifestations of CVD.

The report provides data on the world market for cardiovascular disease markers in U.S. dollars with projections to 2010. Specific segments covered, include:

• Cholesterol/Lipid Markers (Laboratory)
• Cholesterol/Lipid Markers (POC Professional)
• Cholesterol/Lipid Markers (POC OTC)
• C-Reactive Protein/Inflammation Markers
• Enzymes, Special
• Acute Myocardial Infarction Enzymes(Laboratory)
• Acute Myocardial Infarction (POC)
• BNP
• Coagulation Markers
• Homocysteine
• D-Dimer
• Gene Thrombophilia Markers

The report also discussed the clinical, regulatory, and business trends shaping test research, development, and marketing, and profiles the CVD offerings and positions of 46 top companies and innovators worldwide.

The information found in this report is based on data culled from the Kalorama Information’s In Vitro Diagnostic Market Watch database and assembled into a narrative by Kalorama analysts. The database is updated daily, and includes:

• Published content from Kalorama Information’s catalog
• Company issued press releases
• Company web sites and Annual reports
• Syndicated news services
• Industry news and technology sources
• Personal communications from industry contacts

Related Reports:

Trends in the Early Diagnosis of Cardiovascular Disease: Worldwide Market Opportunities
Oct 1, 2001 - KLI450532 - $3,250.00